An Open-label, Phase 1, First in Human Study Investigating the Safety, Tolerability, Pharmacokinetics and Efficacy of NVG-111 in Subjects With Relapsed/Refractory ROR1+ Malignancies
Latest Information Update: 19 Jan 2024
At a glance
- Drugs NVG-111 (Primary) ; Ibrutinib
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Malignant melanoma; Mantle-cell lymphoma; Non-small cell lung cancer
- Focus Adverse reactions; First in man
- Sponsors NovalGen
- 12 Dec 2023 Results (n=12) reporting pharmacokinetics, pharmacodynamics and safety data presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 11 Dec 2023 According to Novalgen media release, results from this trial were presented in an oral presentation at the 65th American Society of Hematology Annual meeting 2023.
- 11 Dec 2023 Results presented in the NovalGen Media Release.